Ring Mountain Capital LLC Has $255,000 Stock Position in Eli Lilly and Company $LLY

Ring Mountain Capital LLC reduced its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 50.8% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 331 shares of the company’s stock after selling 342 shares during the quarter. Ring Mountain Capital LLC’s holdings in Eli Lilly and Company were worth $255,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in LLY. Brighton Jones LLC boosted its holdings in Eli Lilly and Company by 22.0% during the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after purchasing an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC boosted its holdings in Eli Lilly and Company by 2.8% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after purchasing an additional 40 shares during the last quarter. Covestor Ltd boosted its holdings in Eli Lilly and Company by 24.9% during the first quarter. Covestor Ltd now owns 426 shares of the company’s stock worth $352,000 after purchasing an additional 85 shares during the last quarter. Kaufman Rossin Wealth LLC purchased a new position in Eli Lilly and Company during the first quarter worth about $242,000. Finally, Opes Wealth Management LLC boosted its holdings in Eli Lilly and Company by 6.6% during the first quarter. Opes Wealth Management LLC now owns 337 shares of the company’s stock worth $278,000 after purchasing an additional 21 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $906.51 on Wednesday. The company’s 50 day moving average is $788.17 and its 200-day moving average is $772.81. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $935.63. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The firm has a market cap of $857.98 billion, a P/E ratio of 59.25, a price-to-earnings-growth ratio of 1.21 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. During the same quarter in the previous year, the firm posted $1.18 earnings per share. The company’s quarterly revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Sell-side analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be given a $1.50 dividend. The ex-dividend date of this dividend is Friday, November 14th. This represents a $6.00 annualized dividend and a dividend yield of 0.7%. Eli Lilly and Company’s payout ratio is 29.35%.

Analyst Ratings Changes

Several research firms recently weighed in on LLY. Guggenheim restated a “buy” rating and set a $948.00 price target on shares of Eli Lilly and Company in a report on Thursday, October 16th. Hsbc Global Res upgraded shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 27th. Daiwa Capital Markets lowered shares of Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 price objective on the stock. in a research report on Sunday, August 17th. DZ Bank raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 14th. Finally, Morgan Stanley lowered their price objective on shares of Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating on the stock in a research report on Friday, October 3rd. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $940.00.

Insider Buying and Selling

In other news, Director J Erik Fyrwald bought 1,565 shares of the firm’s stock in a transaction that occurred on Tuesday, August 12th. The shares were acquired at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the acquisition, the director owned 74,578 shares of the company’s stock, valued at approximately $47,903,686.74. The trade was a 2.14% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Daniel Skovronsky bought 1,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 12th. The shares were purchased at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the acquisition, the executive vice president directly owned 137,660 shares in the company, valued at $87,331,504. This trade represents a 0.73% increase in their position. The SEC filing for this purchase provides additional information. Over the last quarter, insiders have purchased 4,514 shares of company stock valued at $2,894,841. Corporate insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.